Summary of Findings

🫀 Liver

• Size: 15.4 cm — enlarged (normal upper limit ~15 cm in males; >15 cm = hepatomegaly)
• Echogenicity: Moderate to severe bright echogenicity → consistent with Grade II–III fatty infiltration (steatosis)
• IHBR (Intrahepatic Bile Radicles): Not dilated ✓
• Portal Vein: Normal ✓

🟡 Gallbladder (GB)

• Post-cholecystectomy status — GB is absent (previously removed). No abnormality to comment on.

🟢 Common Bile Duct (CBD)

• 5 mm with smooth distal tapering — Normal (upper limit of normal is 6–8 mm; post-cholecystectomy allows up to ~8–10 mm). No obstruction suggested.

🟠 Pancreas

• Normal echo pattern, shape, size, outline ✓
• Pancreatic duct (P.D) not dilated ✓ — No features of pancreatitis or malignancy.

🟣 Spleen

• 10.5 cm — Normal (normal: up to 11–12 cm). Normal echo pattern, shape, outline. Splenic vein not dilated ✓ — No portal hypertension signs.

🫘 Kidneys

• Right kidney cortical cyst (8–10 mm): Simple cortical cysts are common incidental findings, benign in nature (Bosniak Category I). No follow-up needed unless symptomatic.
• Bilateral small concretions (3–3.5 mm): These are small calculi/microliths. At this size, spontaneous passage is likely. Patient should maintain high fluid intake (>2–3 L/day), and dietary oxalate restriction may be advisable. Repeat USG in 6 months to monitor.
• No hydronephrosis or obstruction — reassuring ✓

💧 Urinary Bladder (UB)

• Wall thickness 4.1 mm — Mildly increased (normal <3 mm when well-filled). Thickened bladder wall in context of BPH indicates bladder outlet obstruction (BOO) with secondary detrusor hypertrophy.
• Pre-void volume: 493 ml — Large bladder capacity
• PVRU (Post-Void Residual Urine): 73 ml — Mildly elevated. Normal is <50 ml; 50–100 ml is borderline significant; >200 ml is clearly abnormal. A PVRU of 73 ml is borderline but clinically relevant in the setting of BPH.

🔵 Prostate

• Weight: 24 gm — Mildly enlarged (normal ~20 gm; Grade I BPH is typically 20–40 gm)
• Median lobe: Mildly enlarged ~5 mm — Median lobe hypertrophy causes bladder outlet obstruction disproportionate to gland size (ball-valve effect at the bladder neck).

Clinical Implications & Recommended Next Steps

For Fatty Liver (Grade II–III):

1. Blood tests: LFTs (AST, ALT, ALP, GGT, bilirubin), fasting glucose, HbA1c, lipid profile, CBC
2. Exclude alcohol-related disease (history)
3. Calculate FIB-4 score (age × AST / [platelets × √ALT]) to stratify fibrosis risk
4. Lifestyle modification: Weight reduction, Mediterranean diet, exercise — the cornerstones of NAFLD management (Sleisenger & Fordtran's GI and Liver Disease)
5. Avoid hepatotoxic drugs (statins only if LFTs allow; consult hepatologist if Grade III persists)

For BPH + LUTS:

1. IPSS questionnaire (International Prostate Symptom Score) to grade symptom severity
2. PSA testing if life expectancy >10 years (to exclude prostate carcinoma)
3. Urine flow rate (uroflowmetry)
4. First-line medical therapy (Sabiston Surgery, per AUA 2023 guidelines):
   • α₁-blockers (tamsulosin, silodosin) — relax bladder neck and prostatic smooth muscle
   • 5α-reductase inhibitors (finasteride/dutasteride) — if prostate >40 gm or prominent median lobe; reduces volume by ~25–30% over 6 months
   • Combination therapy may be considered
5. Behavioral modifications: Timed voiding, fluid restriction before bed, reduce caffeine/alcohol
6. Monitor PVRU: If PVRU rises >200 ml, consider urological referral for surgical intervention (TURP or equivalent)

For Bilateral Renal Concretions:

1. Hydration: >2.5 L/day
2. Metabolic workup if recurrent stones (serum calcium, uric acid, oxalate, 24-hour urine)
3. Repeat USG in 6 months

Key Takeaway

1. Metabolic-related fatty liver disease (NAFLD, Grade II–III) — requires metabolic workup and lifestyle intervention
2. BPH with bladder outlet obstruction — warrants LUTS evaluation and likely α-blocker therapy
3. Bilateral small renal calculi — monitor and hydrate

⚠️ This report is an imaging (USG) opinion only and does not constitute a clinical diagnosis. All management decisions should be made by a qualified treating physician.